Torres Lobatón A, Flores Villa J, Román Bassaure E, Rojo Herrera G, Barra García R, Hernández Aten D
Servicio de Oncología, Hospital General de México, SSA México, D.F.
Ginecol Obstet Mex. 1998 Sep;66:381-8.
The prognostic factors of Endometrial cancer at The General Hospital of Mexico, in accordance with the Surgical Pathologic Staging System of the International Federation of Gynecology and Obstetrics (FIGO, are reported here. One hundred and thirty four patients treated with conventional procedures, were evaluated for end results and in 127 cases, it was applied The Surgical-Pathologic Staging System of The International Federation of Gynecology and Obstetrics (FIGO). We had a follow-up without evidence of disease from 24 months to 10 years with a median of 30 months, in 58/105 adenocarcinomas (55.2%); 5/11 Adenoacanthomas (45.4%) and 4/14 Adenosquamous carcinomas, (28.5%). Same evolution was observed in 36/72 patients with age equal or less than 60 years, (50.0%) and 17/43 with age equal or more than 61 years, (39.5%. Using the current FIGO Staging System, the disease-free Survival was 51.9% (66/127 patients). This number includes 39/51, 76.4% for Stage I, (18/21 Ia, 90%; 13/15 Ib, 86.6% and 8/16 Ic, 50% P = 0.003); 17/23 cases: 73.9% for Stage II, (5/6 IIa, 83.3% and 12/17 IIb, 70.5%); 10/37 cases: 27.0% for Stage III, (5/14 IIIa 35.7%; 2/6IIIb, 33.3% and 3/17 IIc, 17.6%) and 1/17: 5.8% for Stage IV. P = 0.001. The current FIGO Staging System is a useful instrument for predicting natural evolution of endometrial carcinomas. In this series the survival was adversely affected by increasing Stage and age. A poor prognosis in pelvic tumors was related by a deep invasion of myometrial and by parametrial invasion.
本文报告了墨西哥综合医院根据国际妇产科联合会（FIGO）手术病理分期系统得出的子宫内膜癌预后因素。对134例行传统手术治疗的患者进行了最终结果评估，其中127例应用了国际妇产科联合会（FIGO）的手术病理分期系统。在58/105例腺癌（55.2%）、5/11例腺棘癌（45.4%）和4/14例腺鳞癌（28.5%）中，我们进行了24个月至10年的无病随访，中位随访时间为30个月。在72例年龄小于或等于60岁的患者中，36例（50.0%）情况相同；在43例年龄大于或等于61岁的患者中，17例（39.5%）情况相同。使用当前的FIGO分期系统，无病生存率为51.9%（66/127例患者）。这个数字包括：I期39/51例（76.4%），其中Ia期18/21例（90%）、Ib期13/15例（86.6%）、Ic期8/16例（50%，P = 0.003）；II期17/23例（73.9%），其中IIa期5/6例（83.3%）、IIb期12/17例（70.5%）；III期10/37例（27.0%），其中IIIa期5/14例（35.7%）、IIIb期2/6例（33.3%）、IIc期3/17例（17.6%）；IV期1/17例（5.8%）。P = 0.001。当前的FIGO分期系统是预测子宫内膜癌自然病程的有用工具。在本系列中，生存率受到分期增加和年龄增长的不利影响。盆腔肿瘤预后不良与肌层深度浸润和宫旁浸润有关。
